Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.

BACKGROUND Petrelintide is a novel, long-acting amylin analogue being developed for long-term treatment of obesity, leveraging a mechanism of action distinct from incretin-based treatments. This phase 2 trial aimed to evaluate the efficacy and safety of once-weekly petrelintide versus placebo in people with obesity....

W. T. Garvey, J. Ard, L. Connery et al. · 1 citation
Oct 2026

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

BACKGROUND For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits. Survodutide is an investigational gluc...

Sean Wharton, C. L. le Roux, E. Startseva et al. · 0 citations
Open access Sep 2026

Leg muscle assessment by HR-pQCT and DXA: associations between imaging measures and muscle function in adults with obesity—a pilot study

Abstract DXA and HR-pQCT are used for bone assessment but also image adjacent soft tissue. This pilot study examined association between HR-pQCT-measured leg muscle cross-sectional area (CSA) and density vs DXA-derived lean mass, and explored associations with muscle strength, power, and physical performance in adults...

Søren Gam, Joshua R. Stapleton, Vivian Jing et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.